- Home
- TRV vs MRNA Comparison
TRV vs MRNA Comparison
Compare TRV & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRV | MRNA |
|---|---|---|
| Founded | 1853 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.3B | 61.6B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TRV | MRNA |
|---|---|---|
| Price | $359.80 | $198.59 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 12 |
| Target Price | ★ $308.13 | $34.27 |
| AVG Volume (30 Days) | 1.2M | ★ 13.5M |
| Earning Date | 04-16-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 27.76 | 21.77 |
| EPS | ★ 18.01 | N/A |
| Revenue | ★ $48,828,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | $3.38 | $15.43 |
| P/E Ratio | $20.16 | ★ N/A |
| Revenue Growth | ★ 5.18 | 4.29 |
| 52 Week Low | $252.26 | $22.28 |
| 52 Week High | $398.70 | $202.67 |
Technical Indicators
Market Signals| Indicator | TRV | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.64 | 75.87 |
| Support Level | $359.38 | $43.35 |
| Resistance Level | $374.94 | N/A |
| Average True Range (ATR) | 6.03 | 11.47 |
| MACD | -1.71 | 2.59 |
| Stochastic Oscillator | 0.57 | 86.71 |
Price Performance
Historical ComparisonAbout TRV The Travelers Companies Inc.
Travelers offers a broad product range and participates in both commercial and personal insurance lines. Its commercial operations offer a variety of coverage types for companies of any size but concentrate on serving midsize businesses. Its personal lines are roughly evenly split between auto and homeowners insurance.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.